Home › NDC Lookup › J-codes › J9258
J9258

J9258 – Injection, paclitaxel protein-bound particles (teva) not therapeutically · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 1 NDC crosswalked

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J9258 summary

J9258 is a HCPCS Level II J-code used to bill paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9258: Paclitaxel

Code J9258 NDC-Crosswalk 1 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9258
DescriptorInjection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg
Billing unitNot available in current dataset
Payment limit / unit Not available in current dataset
Mapped NDCs1
Data periodNot available in current dataset
Last updatedSource date not available

💊 About Paclitaxel DRUG GUIDE

Paclitaxel injection is used to treat advanced ovarian cancer (including as first-line therapy in combination with cisplatin), breast cancer after prior chemotherapy has failed, and non-small cell lung cancer in patients who are not candidates for surgery or radiation (in combination with cisplatin).

It is also used as second-line treatment for AIDS-related Kaposi's sarcoma.

Paclitaxel injection is additionally approved for the adjuvant (preventive, post-surgery) treatment of node-positive breast cancer, given sequentially with standard chemotherapy.Abraxane, paclitaxel protein-bound particles for injectable suspension (albumin-bound), and related albumin-bound products are indicated for metastatic breast cancer after prior combination chemotherapy has failed, locally advanced or metastatic non-small cell lung cancer as first-line treatment in combination with carboplatin, and metastatic adenocarcinoma of the pancreas as first-line treatment in combination with gemcitabine.

Read the full Paclitaxel drug guide →
Clinical overview from our editorial drug guide for Paclitaxel. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS

Medicare payment limit / unit
—
Est. ASP / unit
—
Est. after 2% sequester
—
HCPCS dosage
—
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly).
Full HCPCS code details (official CMS record)
Long descriptionInjection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment group—
Action codeA — Added this year
Effective date2024-01-01
Date added2024-01-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9258 = 1 unit. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9258 CROSSWALKED NDCs

1 NDC map to J9258. Bill units = how many HCPCS units one package represents.
NDC (11-digit)DrugLabelerPackageStrength Bill units NADAC / unit StatusSource
00480-3290-01 Paclitaxel 100 mg/20mL INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION Teva 1 VIAL, SINGLE-DOSE in 1 CARTON (0480-3290... 100 mg/20mL 100 — ● Active PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

🗺️ Where J9258 is utilized

⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

📊 What bills under J9258

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
Paclitaxel 1
NDC products by labeler
Teva Pharmaceuticals, Inc. 1

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Not available
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
No reportable utilization
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9258 billing FAQ

What is HCPCS code J9258?
J9258 is a HCPCS Level II J-code used to bill Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
Which NDCs bill under J9258?
1 NDC currently map to J9258 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9258 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.